Skip to content

Comparative analysis of CTC-DNA sequencing results and tissue NGS results of different phenotypes

Comparative analysis of CTC-DNA sequencing results and tissue NGS results of different phenotypes

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200062268
Enrollment
Unknown
Registered
2022-07-31
Start date
2022-07-29
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Case series:None

Sponsors

Army Specialty Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged >=18 years, no gendeer limit. 2. For patients with histologically or cytologically proven non-small cell lung cancer, there is no limit to tumor stage. 3. Predicted survival >=3 months. 4. Lung cancer specimens were obtained by surgery or needle biopsy during hospitalization, and peripheral blood samples were collected during hospitalization, and NGS detection of tumor tissue and single cell sequencing detection of peripheral blood CTC were performed. The sequencing results were well preserved and accessible. To improve the reference protocol for their subsequent treatment. The following conditions shall be met for sampling and storage: (1) Surgical sampling: each cancer tissue sample of about 50mg was placed in pre-cold sterile PBS buffer immediately after surgery and tested within 48 hours; (2) Puncture sampling: Puncture samples were soaked in formalin and tested within 48 hours after sampling; (3) Peripheral blood sample: 7.5mL of peripheral blood was collected from the medical anticoagulant collection vessel. The anticoagulant was EDTA K2. Store at 4?, avoid freezing during storage, handling and transportation, and test within 72 hours.

Exclusion criteria

Exclusion criteria: 1. Patients who have previously received radiotherapy and chemotherapy. 2. Patients who had previously received targeted therapy or PD-1/PD-L1 immunotherapy. 3. Patients who had previously received CAR-T cell therapy. 4. Had received systemic corticosteroids (more than 10mg of prednisone equivalent daily) or other immunosuppressive agents for more than 7 days in the 2 weeks prior to sampling (in the absence of active autoimmune disease). 5. Patients with 2 or more previous or current primary tumors.

Design outcomes

Primary

MeasureTime frame
CTC single cell whole gene sequencing;

Countries

China

Contacts

Public ContactTan Qunyou

Army Specialty Medical Center

13983770929@163.com+86 13983770929

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026